Assam Medical College and Hospital (AMCH) in Dibrugarh has begun treating 15 patients under a new designation as a Centre of Excellence for Rare Diseases, becoming the first medical institution in Assam and the entire Northeast to receive the status and giving patients access to central government-funded treatment that was previously available only in a handful of cities elsewhere in India.
Background
Rare diseases — a category that includes genetic disorders such as Spinal Muscular Atrophy, Duchenne Muscular Dystrophy, Gaucher Disease and Mucopolysaccharidosis — typically affect small numbers of patients scattered across wide geographic areas, making specialised diagnosis and treatment difficult to organise regionally. Many require lifelong or prolonged, highly specialised and expensive therapy, placing them financially out of reach for most Indian families without structured government support.
The Government of India's National Policy for Rare Diseases (NPRD), 2021, was designed to address this gap by designating a limited number of Centres of Excellence across the country — AMCH is one of just 15 nationally — equipped to diagnose, register and treat rare disease patients, with the policy providing central financial assistance of up to Rs 50 lakh per patient for treatment. Before AMCH's designation, patients from Assam and the wider Northeast seeking this level of specialised care and central funding had to travel to institutions in other parts of India, adding significant travel, accommodation and logistical costs on top of the disease burden itself — a barrier that likely meant many eligible patients in the region never accessed treatment at all.
Key Details
- AMCH Dibrugarh has been formally designated a Centre of Excellence for Rare Diseases by the Government of India under the National Policy for Rare Diseases (NPRD), 2021.
- It is the first institute in Assam and across the entire Northeast to receive this designation, and one of only 15 such centres identified nationwide.
- Fifteen patients began treatment on the centre's first day of operation, travelling from Guwahati, Tezpur, Nagaon, Sipajhar and neighbouring Tripura state to access care.
- Treatment is provided with full financial assistance from the central government, with NPRD guidelines allowing eligible patients up to Rs 50 lakh in central funding for treatment of qualifying rare conditions.
- AMCH has so far identified a total of 85 patients across the region suffering from various rare conditions, including 21 cases of Spinal Muscular Atrophy (SMA), 50 cases of Duchenne Muscular Dystrophy, three cases of Gaucher Disease and two cases of Mucopolysaccharidosis, among other diagnoses.
- The scale of Duchenne Muscular Dystrophy cases identified (50) and SMA cases (21) suggests a substantial existing patient population in the region that had previously gone without access to a dedicated specialised treatment pathway.
At a Glance
| Detail | Figure |
|---|---|
| Centres of Excellence nationally (NPRD) | 15 |
| AMCH's status | First in Assam and the Northeast |
| Patients treated on first day | 15 |
| Total rare disease patients identified by AMCH | 85 |
| Duchenne Muscular Dystrophy cases identified | 50 |
| Spinal Muscular Atrophy cases identified | 21 |
| Gaucher Disease cases identified | 3 |
| Mucopolysaccharidosis cases identified | 2 |
| Maximum central funding per patient (NPRD) | Up to Rs 50 lakh |
Local Impact
For families across Assam and the Northeast managing a child or relative with a rare genetic disorder, the AMCH designation removes what was previously one of the largest practical barriers to treatment: the need to travel outside the region, often repeatedly over months or years, to reach one of India's existing rare disease centres. Conditions like Duchenne Muscular Dystrophy and Spinal Muscular Atrophy are progressive and require ongoing specialist monitoring, meaning a centre based in Dibrugarh rather than Delhi, Mumbai or Bengaluru meaningfully changes how sustainable long-term treatment is for regional families, particularly those without the financial means for repeated long-distance travel.
The fact that patients on day one travelled not only from across Assam — Guwahati, Tezpur, Nagaon and Sipajhar — but also from neighbouring Tripura underscores AMCH's role as a de facto referral hub for the wider Northeast, not just Assam alone, given the absence of any other NPRD Centre of Excellence anywhere in the eight northeastern states.
What Happens Next
AMCH is expected to continue registering and diagnosing additional rare disease patients from across the region beyond the 85 already identified, as awareness of the centre's availability spreads through referring hospitals and primary care networks in Assam and neighbouring states. Given the scale of already-identified Duchenne Muscular Dystrophy and SMA cases, capacity planning — including specialist staffing, diagnostic infrastructure and coordination with the central government's disbursement process for the Rs 50 lakh per-patient assistance — will likely be an early operational focus as the centre scales up from its initial 15 patients.
Frequently Asked Questions
What is AMCH's new designation?
Assam Medical College and Hospital, Dibrugarh, has been designated a Centre of Excellence for Rare Diseases by the Government of India under the National Policy for Rare Diseases (NPRD), 2021 — the first such centre in Assam and the entire Northeast.
How many patients started treatment and where did they come from?
Fifteen patients began treatment on the centre's first day, travelling from Guwahati, Tezpur, Nagaon and Sipajhar within Assam, as well as from neighbouring Tripura.
How much financial help can patients receive?
Under National Policy for Rare Diseases guidelines, eligible patients can receive central government financial assistance of up to Rs 50 lakh for treatment of qualifying rare conditions.
What rare diseases has AMCH identified in the region?
AMCH has identified 85 patients with various rare conditions so far, including 21 cases of Spinal Muscular Atrophy, 50 cases of Duchenne Muscular Dystrophy, three cases of Gaucher Disease and two cases of Mucopolysaccharidosis.
Why does a regional Centre of Excellence matter for rare disease patients?
Rare diseases often require prolonged, specialised, and repeated treatment. Without a regional centre, Northeast India patients previously had to travel to distant cities like Delhi, Mumbai or Bengaluru for NPRD-funded care, adding significant cost and logistical burden on top of the disease itself.
How many Centres of Excellence for rare diseases exist in India?
AMCH is one of only 15 Centres of Excellence for Rare Diseases identified nationally under the National Policy for Rare Diseases, 2021.
What is Duchenne Muscular Dystrophy?
It is a severe, progressive genetic muscle-wasting disorder, predominantly affecting boys, that leads to worsening muscle weakness over time and typically requires long-term, specialised medical management — accounting for the largest single category (50 cases) among rare disease patients AMCH has identified in the region.
What is Spinal Muscular Atrophy?
It is a genetic neuromuscular disorder that causes progressive muscle weakness and atrophy due to loss of motor neurons, ranging in severity, and is among the conditions now treatable through AMCH's new Centre of Excellence status, with 21 cases identified in the region so far.
Sources
The Sentinel Assam, The Assam Tribune, Medical Dialogues, The Indian Practitioner, National Rare Diseases Portal (rarediseases.mohfw.gov.in).